Specific phobia
The majority of those that develop a specific phobia first experience symptoms in childhood. Often individuals will experience symptoms periodically with periods of remission before complete remission occurs. However, specific phobias that continue into adulthood are likely to experience a more chronic course. Specific phobias in older adults has been linked with a decrease in quality of life. Those with specific phobias are at an increased risk of suicide. Greater impairment is found in those that have multiple phobias. Response to treatment is relatively high but many do not seek treatment due to lack of access, ability to avoid phobia, or unwilling to face feared object for repeated CBT sessions. Comorbidities
Many of those with a phobia often have more than one phobia. There are also a number of psychological and physiological disorders that tend to occur or coexist at higher rates among this population. As with all anxiety disorders the most common psychiatric condition to occur with a phobia is major depressive disorder. Additionally bipolar disorder, substance dependence disorder, obsessive-compulsive disorder, and post traumatic stress disorder have also been found to occur in those with phobias at higher rates. Epidemiology
Phobias are a common form of anxiety disorder, and distributions are heterogeneous by age and gender. An American study by the National Institute of Mental Health (NIMH) found that between 8.7 percent and 18.1 percent of Americans have phobias, making it the most common mental illness among women in all age groups and the second most common illness among men older than 25.
It was developed in 1958 at the Belgian company Janssen Pharmaceutica and submitted to the first of clinical trials in Belgium later that year.Haloperidol was approved by the U.S. Food and Drug Administration (FDA) on 12 April 1967; it was later marketed in the U.S. and other countries under the brand name Haldol by McNeil Laboratories. Society and culture
Cost
Haloperidol is relatively inexpensive, being up to 100 fold less expensive than newer antipsychotics. Brand names
Haloperidol is the INN, BAN, USAN, AAN approved name. It is sold under the tradenames Aloperidin, Bioperidolo, Brotopon, Dozic, Duraperidol (Germany), Einalon S, Eukystol, Haldol (common tradename in the US and UK), Halol, Halosten, Keselan, Linton, Peluces, Serenace and Sigaperidol. Veterinary use
Haloperidol is also used on many different kinds of animals for nonselective tranquilization and diminishing behavioral arousal, in veterinary and other settings including captivity management. References
External links
"Haloperidol". Drug Information Portal. U.S. National Library of Medicine.